SCHEMBL2102340

SCHEMBL2102340

COc1ccc(Cl)cc1-c1ccc(C(=O)N2CCCC2)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 3/20 0.47
TSHR P16473 2/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 2/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
KCNH2 Q12809 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
P2RX7 Q99572 1/20 0.44
GRM5 P41594 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2100428 0.98 KDM4E (0.47) KMT2AMEN1KDM4EALDH1A1CYP1A2
SCHEMBL2100248 0.88 CPS1 (0.53) KMT2AMEN1KDM4EALDH1A1CYP1A2
SCHEMBL2099785 0.85 PTGDR2 (0.60) KMT2AMEN1ALDH1A1LMNATSHR
SCHEMBL3858332 0.84 PTGDR2 (0.48) KMT2AMEN1KDM4ELMNATSHR
SCHEMBL2102807 0.84 PTGDR2 (0.56) LMNATSHRHPGDGAATP53
SCHEMBL3345912 0.84 PIK3CA (0.43) KDM4EALDH1A1LMNAHPGDABL1
SCHEMBL17502702 0.83 KMT2A (0.65) KMT2AMEN1KDM4EALDH1A1CYP1A2
SCHEMBL2103604 0.83 HSP90AA1 (0.50) KMT2AMEN1KDM4ELMNATSHR
SCHEMBL3340902 0.82 HSD11B1 (0.51) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL18215257 0.82 KMT2A (0.63) KMT2AMEN1KDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722741-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2014-05-13 US disclosed
EP-1784388-B3 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2012-09-05 EP disclosed
US-20120178732-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease LUKER TIMOTHY JON (GB) 2012-07-12 US disclosed
US-8163727-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2012-04-24 US disclosed
US-20100160285-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2010-06-24 US disclosed
US-7737135-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2010-06-15 US disclosed
EP-1784388-B1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2009-11-04 EP disclosed
US-20080132480-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178732-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 KMT2A 1697/4885MEN1 4025/4885KDM4E 2344/4885
US-20100160285-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 KMT2A 1697/4885MEN1 4025/4885KDM4E 2344/4885
US-20080132480-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 KMT2A 1697/4885MEN1 4025/4885KDM4E 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.